Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchis-Gomar, Fabian, Lavie, Carl J., Morin, Daniel P., Perez-Quilis, Carme, Laukkanen, Jari A., Perez, Marco V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394926/
https://www.ncbi.nlm.nih.gov/pubmed/32737841
http://dx.doi.org/10.1007/s40256-020-00429-7
_version_ 1783565302803464192
author Sanchis-Gomar, Fabian
Lavie, Carl J.
Morin, Daniel P.
Perez-Quilis, Carme
Laukkanen, Jari A.
Perez, Marco V.
author_facet Sanchis-Gomar, Fabian
Lavie, Carl J.
Morin, Daniel P.
Perez-Quilis, Carme
Laukkanen, Jari A.
Perez, Marco V.
author_sort Sanchis-Gomar, Fabian
collection PubMed
description Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence.
format Online
Article
Text
id pubmed-7394926
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-73949262020-08-03 Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection? Sanchis-Gomar, Fabian Lavie, Carl J. Morin, Daniel P. Perez-Quilis, Carme Laukkanen, Jari A. Perez, Marco V. Am J Cardiovasc Drugs Current Opinion Amiodarone, one of the most widely prescribed antiarrhythmic drugs to treat both ventricular and supraventricular arrhythmias, has been identified as a candidate drug for use against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We present the rationale of using amiodarone in the COVID-19 scenario, as well as whether or not amiodarone administration represents a potential strategy to prevent SARS-CoV-2 infection, rather than simply used to treat patients already symptomatic and/or with severe coronavirus disease 2019 (COVID-19), based on current evidence. Springer International Publishing 2020-08-01 2020 /pmc/articles/PMC7394926/ /pubmed/32737841 http://dx.doi.org/10.1007/s40256-020-00429-7 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Current Opinion
Sanchis-Gomar, Fabian
Lavie, Carl J.
Morin, Daniel P.
Perez-Quilis, Carme
Laukkanen, Jari A.
Perez, Marco V.
Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title_full Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title_fullStr Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title_full_unstemmed Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title_short Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?
title_sort amiodarone in the covid-19 era: treatment for symptomatic patients only, or drug to prevent infection?
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394926/
https://www.ncbi.nlm.nih.gov/pubmed/32737841
http://dx.doi.org/10.1007/s40256-020-00429-7
work_keys_str_mv AT sanchisgomarfabian amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection
AT laviecarlj amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection
AT morindanielp amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection
AT perezquiliscarme amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection
AT laukkanenjaria amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection
AT perezmarcov amiodaroneinthecovid19eratreatmentforsymptomaticpatientsonlyordrugtopreventinfection

Ejemplares similares